Searched for
GLENMARK PHARMA SHARES
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- Glenmark Pharma shares in focus on $1.1 billion deal for oncology drugGlenmark Pharma shares: The company's unit Glenmark Specialty S.A. signed an exclusive licensing deal with China’s Hengrui Pharma for Trast...
- Glenmark Pharma shares in focus after USFDA warning to Indore plantGlenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. Th...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug dealGlenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licen...
- Stock Radar: Breakout from falling trendline makes Glenmark an attractive buy; check target & stop lossGlenmark Pharma Ltd has broken out of an 8-month consolidation, breaching a downward trendline. Experts suggest a buy for short-to-medium t...
- Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drugGlenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Glenmark Pharma shares in focus after 34% stake acquisition in O2 renewable energy XXIVThe acquisition supports Glenmark’s goal of achieving carbon neutrality by 2030. The deal follows a Securities Subscription & Shareholder’s...
- Glenmark closes 3% lower post API arm sale dealAccording to analysts, the sale of Glenmark Life could impact the profitability of Glenmark Pharma in FY25 but lower interest payments coul...
- Glenmark Pharma weighs selling stake in Glenmark Life in bid to reduce debtIt has been aiming to reduce its debt, including through the sale of some dermatology brands to Eris Lifesciences for Rs 3,400 crore in Jan...
- Glenmark Pharma reports 31% drop in net profit to Rs 211 croreGlenmark is ranked 14th with a market share of 2.17% Sales from North America fell 10.2% YoY to Rs 663 crore. Europe sales saw 8% YoY to Rs...
- Buy Glenmark Pharma, target price Rs 560: Yes SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a mid-cap company (with a market cap of Rs 14826.53 crore) operating in ph...
Load More
